ライフサイエンスコーパス: Nfe2l2

1 nd the transcription factor Nrf2 (encoded by Nfe2l2).

2 rythroid-derived 2 like 2 [also called NRF2 (NFE2L2)].

3 with either wild-type (WT)-, G31A-, or T80K-NFE2L2.

4 l regulation by Rela, Relb, Junb, Bach1, and Nfe2l2.

5 n of the oxidative stress targets TXNRD1 and NFE2L2.

6 genetic deficiency of Vhl, Hif1a, Nos2, and Nfe2l2.

7 the master antioxidant transcription factor NFE2L2.

8 and EHF, CTNNB1, APC, NSD1, KAT8, STK11 and NFE2L2.

9 , and mutations in EP300 (16%), FBXW7 (15%), NFE2L2 (4%), TP53 (5%) and ERBB2 (6%).

10 ar factor-erythroid 2-related factor 2 (Nrf2/NFE2L2), a redox-sensitive transcription factor plays a

11 Nuclear factor, erythroid 2-like 2 (NFE2L2), a transcription factor also known as NF-E2-rela

12 We showed that activation of NFE2L2, a frequent event in lung squamous cancers, confe

13 This phosphorylation event activates NFE2L2, a key transcription factor in the oxidative stre

14 This was accompanied by nuclear Nfe2l2 accumulation and led us to identify abundant Nfe2

15 ) and NFE2 like BZIP transcription factor 2 (NFE2L2) activation and BTB domain and CNC homolog 1 (BAC

16 r nuclear factor-erythroid-derived 2-like 2 (NFE2L2 alias NRF-2).

17 rotein stability of the transcription factor NFE2L2 (also known as NRF2), leading to the upregulation

18 r nuclear factor-erythroid derived 2-like 2 (nfe2l2, also known as Nrf2) in the nucleus.

19 otein NFE2 like bZIP transcription factor 2 (NFE2L2, also known as NRF2) is a key regulator of ferrop

20 (95% CI, 25%-84%) among patients with KEAP1/NFE2L2-altered tumors compared with 27% (95% CI, 17%-42%

21 ed by sustained activity of Nfix, Runx1, and Nfe2l2 and dissociation of the transcriptional repressor

22 iRNA knockdown confirmed that the TFs FOSL1, NFE2L2 and ELF3 mediate cellular proliferation and also

23 monstrate that BTG2 is a binding partner for NFE2L2 and increases its transcriptional activity.

24 equires the antioxidant transcription factor NFE2L2 and is associated with up-regulation of the expre

25 Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes

26 ed with the discovery of SOX2 amplification, NFE2L2 and KEAP1 mutations, PI3K pathway changes, FGFR1

27 trees targeted oncogenes, including PIK3CA, NFE2L2 and MTOR, among others.

28 Coexpression of mutant NFE2L2 and mutant CTNNB1 led to clinically relevant HCC

29 nt of lung injury and for SNPs in IL8, MBL2, NFE2L2 and NAMPT with severity in ALI outcomes.

30 accumulation and led us to identify abundant Nfe2l2 and other mitochondrial biogenesis transcription

31 demonstrated an interaction between hepatic Nfe2l2 and PGC-1alpha in WT mice that was greatly reduce

32 cantly mutated genes, including TP53, CDH10, NFE2L2 and PTEN.

33 ytes, revealing decreased mRNA expression of NFE2L2 and several NFE2L2 target genes.

34 , we identify recurrent alterations in KEAP1/NFE2L2 and WNT pathway in GBC.

35 gulated (p <= 0.001) antioxidant genes (SOD, NFE2L2) and downregulated (p <= 0.001) apoptotic markers

36 NF-E2 p45-related factor 2 (NRF2; encoded by NFE2L2) and its principal negative regulator, the E3 lig

37 the transcription factor Nrf2 (also known as Nfe2l2) and its repressor protein Keap1.

38 NF-E2-related factor 2 (NRF2; also called NFE2L2) and related NRF family members regulate antioxid

39 redicted activators (HNF1, HNF4, FOXA, GATA, NFE2L2) and two predicted repressors (GFI1, ZFP161) and

40 fying four transcription factors, MYC, KLF4, NFE2L2, and JDP2, with high regulatory activity across t

41 itors of phosphoinositide 3-kinase (PI3K) as NFE2L2 antagonists.

42 4-derived ROS function in concert to drive a NFE2L2 antioxidant defense response to attenuate oxidati

43 ich in turn generated H2O2 to exacerbate the NFE2L2 antioxidant defense response.

44 tomics and pathway analysis identified NRF2 (NFE2L2) as an upstream transcription factor that was fun

45 designated 50 tumor-associated genes as the NFE2L2-associated molecular signature (NAMS).

46 TFCP2L1, HOXB9 and MITF and gain of MYC and NFE2L2-associated oncogenic and ferroptosis resistance p

47 everal transcriptional regulators, including NFE2L2, ATF4, Srebf1 and Rictor were identified as poten

48 (nuclear factor (erythroid-derived) 2-like; NFE2L2) binding to deoxyribonucleic acid-regulatory sequ

49 ping studies revealed that Z-DNA-forming and NFE2L2-binding motifs were positively associated with th

50 Coexpression of mutated CTNNB1 with mutant NFE2L2, but not WT-NFE2L2, led to HCC development and mo

51 omote ferroptosis resistance, independent of NFE2L2, by maintaining the expression of glutathione per

52 NFE2L2 can also promote ferroptosis resistance but does

53 EAP1 ubiquitin ligase or its substrate NRF2 (NFE2L2) commonly occur in human cancer, resulting in con

54 and validated for the first time that human NFE2L2 could be targeted by miR153/miR27a/miR142-5p/miR1

55 NFE2L2-CTNNB1 HCC mice were treated with mTOR inhibitor

56 g to NRP2, using a humanized mAb, results in NFE2L2 degradation via KEAP1, rendering cell lines and o

57 ation of antioxidant gene expression is also NFE2L2-dependent.

58 e, implicating PGC-1alpha in facilitation of Nfe2l2 DNA binding.

59 Mutations in KEAP1 and NFE2L2 (encoding the protein Nrf2) are prevalent in both

60 Co-transfections with an Nfe2l2 expression vector and a luciferase reporter const

61 8 (PAX8)-nuclear factor, erythroid 2 like 2 (NFE2L2) fusion in thyroid carcinoma.

62 hen developed a risk scoring system based on NFE2L2 gene expression profiling and designated 50 tumor

63 resulting in the stabilization of Nrf2, the Nfe2l2 gene product, which controls oxidative homeostasi

64 Our study provides evidence that NFE2L2 genotype interacts with SHS exposure to affect bo

65 In stratified analyses, NFE2L2 genotype was associated with daily asthma symptom

66 Interactions between SHS exposure and NFE2L2 genotype were also associated with an increased r

67 e analysis, and interactions between SHS and NFE2L2 genotype were evaluated using logistic regression

68 Consequently, genetic inhibition of the NFE2L2-GSH-SLC25A39 pathway enhances cuproptosis-mediate

69 n of a master regulator of cellular defence, NFE2L2, has little effect, suggesting redundancy in the

70 ulator of nuclear factor erythroid 2-like 2 (NFE2L2; hereafter NRF2), which is the master transcripti

71 e, the recognition that alterations in KEAP1-NFE2L2 in LUSCs affected antitumor immune responses crea

72 a novel role for BTG2 as a co-activator for NFE2L2 in up-regulating cellular antioxidant defenses.

73 These results suggest that NFE2L1 and NFE2L2 independently regulate ferroptosis.

74 ncer region provide additional evidence that Nfe2l2 is involved in the regulation of Ucp1 by cAMP-med

75 stress-regulated transcription factor NRF2 (NFE2L2) is a prominent feature of many types of cancer,

76 nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) is important for the defence against oxidative s

77 he KEAP1/NFE2L2 mutational status (Mut(KEAP1/NFE2L2)) is significantly correlated with LR in patients

78 Transcription factor NRF2, encoded by NFE2L2, is the master regulator of defense against stres

79 The NFE2L2-KEAP1 and MLL pathways are recurrently mutated in

80 ion and glutathione pathways and harbor more NFE2L2/KEAP1 alterations and copy gain in the 3q2 locus.

81 s of which were attributable to mutations in NFE2L2/KEAP1.

82 th ligand 1 expression, and pathogenic KEAP1/NFE2L2, KRAS, and DNA damage repair pathway alterations

83 Somatic mutations of NFE2L2 leading to NRF2 accumulation promote cell surviva

84 Somatic mutation of NFE2L2 led to Nrf2 activation and radioresistance in HNS

85 utated CTNNB1 with mutant NFE2L2, but not WT-NFE2L2, led to HCC development and mortality by 12-14 we

86 epithelial cells, leading to increased Nrf2 (NFE2L2) levels and subsequent Nrf2-dependent expression

87 We hypothesized that NFE2L2-mediated gene expression would reflect cancer sev

88 d a meta-analysis of microarray data for 240 NFE2L2-mediated genes that were enriched in tumor tissue

89 Inhibition of Nfe2l2-mediated oxidative stress in the fetal heart and

90 ndrial antioxidant enzyme expression through Nfe2l2-mediated SOD-2 expression in sepsis.

91 actor erythroid 2-related factor 2-mediated (NFE2L2-mediated) transcription of antioxidant response g

92 Nfe2l2(-/-) mice compared with WT mice, showed more live

93 Nfe2l2(-/-) mice in sepsis also generated higher hepatic

94 in Nfe2l2-silenced cells and post-sepsis in Nfe2l2(-/-) mice.

95 The KEAP1/NFE2L2 mutational status (Mut(KEAP1/NFE2L2)) is signific

96 NFE2L2 mutations are predictive biomarkers of radioresis

97 Moreover, NFE2L2 mutations correlate with the allele status of a n

98 s study provides insights into the impact of NFE2L2 mutations on radioresistance and suggests that CB

99 ical testing of CB-839 with RT in HNSCC with NFE2L2 mutations.

100 ow that lung tumours prime accessibility for Nfe2l2 (NRF2) in bone marrow myeloid progenitors as a cy

101 fect on different components of the CUL3 and NFE2L2 (NRF2) pathway was assessed in affected individua

102 ling by the antioxidant transcription factor NFE2L2 (NRF2) through the antioxidant response element i

103 ested the idea that HO-1, acting through the Nfe2l2 (Nrf2) transcription factor, links anti-inflammat

104 ion revealed consensus binding sites for the Nfe2l2 (Nrf2) transcription factor.

105 ha (Hnf4a) and Hnf1a, as well as Nr3c1 (Gr), Nfe2l2 (Nrf2), peroxisome proliferator-activated recepto

106 Nuclear factor, erythroid 2 like 2 (Nfe2l2, Nrf2) is a transcriptional regulator that is kno

107 osome 1), nuclear factor erythroid 2 like 2 (NFE2L2, NRF2), and O6-methlyguanine-DNA-methyltransferas

108 sequencing defined the transcription factor NFE2L2/NRF2 as a critical driver of erythrophagocytes, a

109 ythroid-2-related factor 1 (NFE2L1/NRF1) and NFE2L2/NRF2 can both regulate oxidative stress pathways

110 a critical driver of erythrophagocytes, and Nfe2l2/Nrf2 deficiency restored heme-suppressed inflamma

111 NFE2L2/NRF2 knockout cells also have low VAMP8 expressio

112 NFE2L2/NRF2 knockout cells have low HERC2 expression, le

113 Therefore, deletion of NFE2L2/NRF2 results in apoferritin accumulation in the a

114 enic Kras induced the redox master regulator Nfe2l2/Nrf2 to stimulate pancreatic and lung cancer init

115 d oxidative stress-induced mitophagy through NFE2L2/NRF2 transactivation.

116 Nuclear factor erythroid 2-related factor 2 (NFE2L2/NRF2) is a critical mediator of the cellular oxid

117 Loss of KEAP1, a negative regulator of NFE2L2/NRF2, modulated the response to BRAF, MEK, EGFR,

118 and IL1Ra promoters, which for IL10 included Nfe2l2, nuclear respiratory factor (NRF)-2 (Gabpa), and

119 decreased NRF2 protein levels and sensitized NFE2L2 or KEAP1-mutant cells to radiation.

120 nuclear factor, erythroid-derived 2, like 2 (Nfe2l2 or Nrf2) and up-regulation of the antioxidant pro

121 ther the nuclear factor, erythroid 2-like 2 (NFE2L2 or NRF2), which is sensitive to oxidative stress,

122 nuclear factor erythroid 2-related factor 2 (NFE2L2 or NRF2).

123 nditional gene deletion validated a role for NFE2L2 (or NRF2), a master regulator of antioxidant resp

124 nuclear factor erythroid-2-related factor-2 (NFE2L2) or Kelch like-ECH-associated protein 1 (KEAP1),

125 associated with radiation resistance (KEAP1/NFE2L2) or radiation sensitivity (DNA damage repair path

126 AD-related genes (C4a/C4b, Cd74, Ctss, Gfap, Nfe2l2, Phyhd1, S100b, Tf, Tgfbr2, and Vim) was increase

127 KRAS, NRAS, HRAS, BRAF, DDR2, ERBB2, KEAP1, NFE2L2, PIK3CA, PTEN, RHOA, BRCA1, BRCA2 and TP53) as we

128 The transcription factor NFE2L2 plays a central role in upregulating anti-ferropt

129 immunoprecipitation demonstrated diminished Nfe2l2 protein binding to the antioxidant response eleme

130 Gene mutations in SMAD2, MTOR, NFE2L2, RB1, KEAP1, TERT, and RASA1 might impair antitum

131 ntioxidant response element (ARE) of several NFE2L2-responsive genes.

132 gene expression levels to predict Mut(KEAP1/NFE2L2), resulting in a binary output.

133 cancers acquire mutations in either Keap1 or Nfe2l2, resulting in the stabilization of Nrf2, the Nfe2

134 In cells, Hmox1 or Nfe2l2 RNA silencing prevented IL-10 and IL-1Ra up-regul

135 wer ventilator-free days (VFDs), and SNPs in NFE2L2 (rs6721961) and NAMPT (rs61330082) were nominally

136 nding factors, we find that TP53, EP300, and NFE2L2 show higher mutational frequencies in Asian patie

137 nvolved in stress response pathways (such as NFE2L2 signalling, autophagy and hypoxia) and the epithe

138 ation, and HO-1 induction failed post-LPS in Nfe2l2-silenced cells and post-sepsis in Nfe2l2(-/-) mic

139 ), SOX17 and FOXA2 (endometrial cancer), and NFE2L2, SOX2, and TP63 (squamous cell lung cancer).

140 Four NFE2L2 tagging SNPs were included in the analysis, and i

141 reased mRNA expression of NFE2L2 and several NFE2L2 target genes.

142 GPX-1 or by treating mice with an agonist of NFE2L2, the master regulator of antioxidant defense.

143 Mitochondria-derived ROS activated NFE2L2 to induce the expression of NOX4, which in turn g

144 w that the ability of BTG2 to associate with NFE2L2, to protect cells against oxidative stress, and t

145 The NRF2 (also known as NFE2L2) transcription factor is a critical regulator of

146 nuclear factor (erythroid 2)-like 2 (NRF2 or NFE2L2) transcription factor regulates the expression of

147 nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) transcription factor resulting from accumulated

148 hnRNP K protein was bound to antioxidant NFE2L2 transcripts encoding Nrf2 antioxidant transcripti

149 i-inflammatory regulators like PPARgamma and NFE2L2 upon Ingenuity Pathway Analysis (IPA).

150 approach enables the prediction of Mut(KEAP1/NFE2L2) using PET/CT-extracted radiomics features and ef

151 nuclear factor erythroid 2-related factor 2 (NFE2L2) were elevated in hepatocytes early in disease pr

152 These transcripts and Nrf2 (Nfe2l2) were increased by systemic application of tunica

153 Here, we found that mutations in NFE2L2, which encodes Nrf2, are associated with a signif

154 es are regulated by the transcription factor Nfe2l2, which is also increased in expression at 3 weeks

155 (95% CI, 17%-42%) among patients with KEAP1/NFE2L2-wildtype tumors (P = .05).

156 Prediction of Mut(KEAP1/NFE2L2) with noninvasive modalities could help to furthe